HBP:CA:TSX-Helix BioPharma Corp (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 0.78

Change

0.00 (0.00)%

Market Cap

CAD 0.11B

Volume

0.05M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

+0.23 (+1.27%)

CAD2.30B N/A N/A
TRIL:CA Trillium Therapeutics Inc

-0.97 (-6.30%)

CAD1.55B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
APS:CA Aptose Biosciences Inc

-0.14 (-2.69%)

CAD0.46B N/A N/A
BLU:CA BELLUS Health Inc

+0.01 (+0.20%)

CAD0.39B N/A N/A
IMV:CA IMV Inc

-0.20 (-4.49%)

CAD0.30B -99,999.99 N/A
MDNA:CA Medicenna Therapeutics Corp

-0.07 (-1.35%)

CAD0.28B 5.40 N/A
FRX:CA Fennec Pharmaceuticals Inc

-0.61 (-5.94%)

CAD0.27B 30.20 N/A
RVX:CA Resverlogix Corp

-0.04 (-3.92%)

CAD0.24B 56.67 27.58
ATE:CA Antibe Therapeutics Inc

-0.41 (-7.55%)

CAD0.21B N/A N/A

ETFs Containing HBP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.00% 88% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.00% 88% B+ 95% A
Trailing 12 Months  
Capital Gain -48.00% 18% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.00% 18% F 2% F
Trailing 5 Years  
Capital Gain -58.73% 17% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.73% 17% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain 3.81% 18% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.81% 18% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 88.52% 53% F 6% F
Risk Adjusted Return 4.30% 18% F 34% F
Market Capitalization 0.11B 33% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 46.21 13% F 2% F
Price / Cash Flow Ratio -10.17 33% F 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -546.84% 7% F 1% F
Return on Invested Capital 1,942.73% 94% A 100% A+
Return on Assets -160.08% 11% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.03 100% A+ 93% A
Short Percent N/A N/A N/A N/A N/A
Beta -0.13 94% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.